Market Research Reports, Inc.

MarketResearchReports.Com: Global Anti-Hypertensives Market Is Expected to Reach $37.6 Billion in 2020, Reveals New Report

Market Research Reports, Inc. has announced the addition of “Antihypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries” research report to their website


Lewes, DE -- (SBWIRE) -- 06/09/2014 -- Market to Decline due to Key Patent Expiries

The global anti-hypertensives market is expected to decline during the forecast period at a negative Compound Annual Growth Rate (CAGR) of 0.9% from $40 billion in 2013 to $37.6 billion in 2020, with growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline thereafter. The initial growth will be due to the increased penetration of fixed-dose combination drugs (Amturnide, Exforge Tribenzor, Azor, Tekturna HCT, Edarbyclor, Twynsta, Benicar HCT, Micardis Plus, Tekamlo, Valturna), a rise in the prevalence population from 181 million to 190 million at a CAGR of 0.6%, and two new expected launches in the pipeline (azilsartan + amlodipine, and AHU377+ valsartan). However, due to the expiry of the exclusivity of major drugs both before and during the forecast period (Cozaar in 2010; Diovan, Avapro and Atacand in 2012; Exforge in 2014; Benicar in 2016; and Tekturna and Tekturna HCT in 2018), increased generic penetration and a low diagnosis rate, the market will decline from 2017. Hypertension is a chronic disease and so its management required prolonged treatment. The management of hypertension requires prolonged treatment as it is a chronic disease, ultimately ensuring market stability despite generic erosion.

Anti-Hypertensives Pipeline: Limited Scope

Most of the drugs in the anti-hypertensives pipeline are generics (77%), and only 20% of molecules are novel drug candidates. The novel approach is limited to a few targets such as nondihydropyridine dual L/T-type calcium channel blockers (ACT-280778), Rho-associated kinase inhibitors (AN-3485), and vitamin D receptor agonists (CARD-024), to name a few. Novartis’ AHU-377, a novel molecule that functions as a Neutral Endopeptidase Inhibitor (NEP), is currently in Phase III as a combination drug with Novartis’ blockbuster valsartan. Most of the drug dosages in the anti-hypertension market comprise one oral tablet once daily.

Browse this report:

For all Healthcare Reports at:

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Follow us on YouTube :